VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108060
Title:
VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.
Authors:
Anderson, Heather; Thatcher, Nick; Rankin, Elaine M; Wagstaff, John; Scarffe, J Howard; Crowther, Derek
Abstract:
Twenty patients presenting with metastatic carcinoma from an unknown primary site were studied. All patients were treated with a triple chemotherapy regimen of vincristine, adriamycin and cyclophosphamide repeated at three-week intervals. The response rate was 50%, and the four patients achieving complete response are alive and disease-free at 13, 16, 36 and 39 months. Toxicity was minimal and the majority of patients' performance status improved with the chemotherapy. VAC chemotherapy is indicated for patients with metastases, particularly of soft tissues originating from a carcinoma from an unknown primary site.
Affiliation:
Cancer Research Campaign, Dept. of Medical Oncology, Manchester University and Christie Hospital & Holt Radium Institute, Wilmslow Road, Manchester M20 9BX, U.K.
Citation:
VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. 1983, 19 (1):49-52 Eur J Cancer Clin Oncol
Journal:
European Journal of Cancer & Clinical Oncology
Issue Date:
Jan-1983
URI:
http://hdl.handle.net/10541/108060
DOI:
10.1016/0277-5379(83)90397-8
PubMed ID:
6687868
Type:
Article
Language:
en
ISSN:
0277-5379
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorThatcher, Nicken
dc.contributor.authorRankin, Elaine Men
dc.contributor.authorWagstaff, Johnen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-21T12:31:59Z-
dc.date.available2010-07-21T12:31:59Z-
dc.date.issued1983-01-
dc.identifier.citationVAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. 1983, 19 (1):49-52 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379-
dc.identifier.pmid6687868-
dc.identifier.doi10.1016/0277-5379(83)90397-8-
dc.identifier.urihttp://hdl.handle.net/10541/108060-
dc.description.abstractTwenty patients presenting with metastatic carcinoma from an unknown primary site were studied. All patients were treated with a triple chemotherapy regimen of vincristine, adriamycin and cyclophosphamide repeated at three-week intervals. The response rate was 50%, and the four patients achieving complete response are alive and disease-free at 13, 16, 36 and 39 months. Toxicity was minimal and the majority of patients' performance status improved with the chemotherapy. VAC chemotherapy is indicated for patients with metastases, particularly of soft tissues originating from a carcinoma from an unknown primary site.en
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCyclophosphamide-
dc.subject.meshDactinomycin-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshVincristine-
dc.titleVAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Dept. of Medical Oncology, Manchester University and Christie Hospital & Holt Radium Institute, Wilmslow Road, Manchester M20 9BX, U.K.en
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.